新兴阿尔茨海默病治疗中淀粉样蛋白相关影像异常的检测与报告建议
单克隆抗体治疗阿尔茨海默病需脑MRI评估 eligibility 并监测淀粉样蛋白相关影像异常(ARIA)。ARIA 分两型:水肿/渗出型在 T2-FLAIR 上识别,出血型在 T2* GRE 上识别。本文基于临床试验文献和专家经验,总结 ARIA 影像表现、解读陷阱,并提供标准化成像方案和报告模板建议。
要点
- ARIA 分水肿/渗出型(T2-FLAIR)和出血型(T2* GRE),需分别识别。
- ARIA 严重程度评分结合临床状态决定患者管理和继续用药资格。
- 放射科医生需熟悉 ARIA 影像表现、合适成像方案及标准化报告。
核心结论
- 标准化成像和报告对 ARIA 评估至关重要,因其严重程度评分用于指导患者管理和单克隆抗体继续用药资格。
研究设计与样本
- 基于临床试验文献和临床试验影像专家经验的总结,提出标准化成像方案和 ARIA 报告模板建议。
关键影像表现/征象
- ARIA 水肿/渗出型表现为治疗诱导的短暂水肿或脑沟渗出,在 T2-FLAIR 上识别。
- ARIA 出血型表现为治疗诱导的微出血或表面铁沉积,在 T2* 梯度回波序列上识别。
临床应用与阅片要点
- 对接受单克隆抗体治疗的阿尔茨海默病患者,脑 MRI 用于 eligibility 评估和 ARIA 监测。
- 阅片时需注意 ARIA 的潜在解读陷阱,并采用标准化成像协议和报告模板。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Monoclonal antibodies are emerging disease-modifying therapies for Alzheimer disease that require brain MR imaging for eligibility assessment as well as for monitoring for amyloid-related imaging abnormalities. Amyloid-related imaging abnormalities result from treatment-related loss of vascular integrity and may occur in 2 forms. Amyloid-related imaging abnormalities with edema or effusion are transient, treatment-induced edema or sulcal effusion, identified on T2-FLAIR. Amyloid-related imaging abnormalities with hemorrhage are treatment-induced microhemorrhages or superficial siderosis identified on T2* gradient recalled-echo. As monoclonal antibodies become more widely available, treatment screening and monitoring brain MR imaging examinations may greatly increase neuroradiology practice volumes. Radiologists must become familiar with the imaging appearance of amyloid-related imaging abnormalities, how to select an appropriate imaging protocol, and report findings in clinical practice. On the basis of clinical trial literature and expert experience from clinical trial imaging, we summarize imaging findings of amyloid-related imaging abnormalities, describe potential interpretation pitfalls, and provide recommendations for a standardized imaging protocol and an amyloid-related imaging abnormalities reporting template. Standardized imaging and reporting of these findings are important because an amyloid-related imaging abnormalities severity score, derived from the imaging findings, is used along with clinical status to determine patient management and eligibility for continued monoclonal antibody dosing.
引用
- Cogswell, Barakos, Barkhof, et al. Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice. AJNR Am J Neuroradiol. 2022. PMID: 35953274. doi:10.3174/ajnr.A7586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。